JPRN-jRCT2041210086招募中3 期
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
Mona D. Shah0 个研究点目标入组 45 人开始时间: 2021年10月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 <= 17age old（—）
- 性别
- All
入选标准
- •Body weight >= 5 kg at screening.
- •Vaccination against Neisseria meningitidis.
- •Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
排除标准
- •TMA associated with non-aHUS related renal disease.
- •Positive direct Coombs test.
- •Chronic dialysis and/or end stage renal disease.
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)EUCTR2020-002475-35-HUF. Hoffmann-La Roche Ltd90
进行中（未招募）
3 期
Clinical trial study for atypical hemolytic uremic syndrome in childrens aged more than 28 days to less than 18 years.CTRI/2023/12/060590F HoffmannLa Roche Ltd
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)MedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2020-002437-15-HUF.Hoffmann-La Roche Ltd35
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)MedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2020-002437-15-BEF.Hoffmann-La Roche Ltd45
尚未招募
3 期
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY,PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME(aHUS)D593 Haemolytic-uraemic syndromeHaemolytic-uraemic syndromeD593PER-019-21F. HOFFMANN-LA ROCHE LTD.